Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline

NEXT STORY
CytomX Therapeutics Announces First Quarter 2019 Financial Results
PREV STORY
Guardant Health Reports First Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy

author_avatar
NASDAQ Market News

FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

author_avatar
NASDAQ Market News

New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

author_avatar
NASDAQ Market News